The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: RBC Upgrades IMI And Downgrades Rotork

Tue, 14th Jul 2020 09:49

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

CREDIT SUISSE RAISES HALMA PRICE TARGET TO 2530 (2030) PENCE - 'OUTPERFORM'

----------

BERNSTEIN RAISES JOHNSON MATTHEY TARGET TO 3500 (3400) PENCE - 'OUTPERFORM'

----------

BERNSTEIN RAISES CRODA INTERNATIONAL TARGET TO 5100 (4500) PENCE - 'MARKET-PERFORM'

----------

BARCLAYS RAISES FLUTTER PRICE TARGET TO 10500 (10000) PENCE - 'EQUAL WEIGHT'

----------

RBC RAISES SMITHS PRICE TARGET TO 1530 (1300) PENCE - 'OUTPERFORM'

----------

GOLDMAN SACHS CUTS STANDARD CHARTERED PRICE TARGET TO 690 (730) PENCE - 'BUY'

----------

GOLDMAN CUTS ROYAL BANK OF SCOTLAND PRICE TARGET TO 195 (215) PENCE - 'BUY'

----------

GOLDMAN CUTS LLOYDS BANKING PRICE TARGET TO 29 (32) PENCE - 'SELL'

----------

GOLDMAN CUTS BARCLAYS PRICE TARGET TO 135 (150) PENCE - 'NEUTRAL'

----------

GOLDMAN CUTS HSBC TO 'BUY' ('CONVICTION BUY LIST') - PRICE TARGET 565 (695) PENCE

----------

DEUTSCHE BANK CUTS BARCLAYS PRICE TARGET TO 135 (208) PENCE - 'BUY'

----------

DEUTSCHE BANK RESUMES STANDARD CHARTERED WITH 'HOLD' - TARGET 415 PENCE

----------

DEUTSCHE BANK RESUMES RBS WITH 'SELL' - TARGET 100 PENCE

----------

DEUTSCHE BANK REINITIATES LLOYDS BANKING WITH 'HOLD' - PRICE TARGET 34 PENCE

----------

DEUTSCHE BANK REINITIATES HSBC WITH 'SELL' - PRICE TARGET 335 PENCE

----------

JPMORGAN RAISES LEGAL & GENERAL TARGET TO 202 (200) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

DEUTSCHE BANK RAISES G4S TO 'BUY' ('HOLD') - TARGET 160 (140) PENCE

----------

DEUTSCHE BANK RESUMES VIRGIN MONEY WITH 'BUY' - TARGET 105 PENCE

----------

JPMORGAN CUTS JOHN WOOD PRICE TARGET TO 400 (590) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES AVON RUBBER PRICE TARGET TO 3510 (2435) PENCE - 'HOLD'

----------

BERENBERG CUTS PRIMARY HEALTH PROPERTIES TO 'HOLD' ('BUY') - TARGET 155 (150) PENCE

----------

BERENBERG CUTS CENTAMIN TO 'HOLD' ('BUY') - TARGET 200 (190) PENCE

----------

BARCLAYS CUTS WILLIAM HILL PRICE TARGET TO 200 (210) PENCE - 'OVERWEIGHT'

----------

RBC RAISES BODYCOTE PRICE TARGET TO 710 (650) PENCE - 'OUTPERFORM'

----------

RBC RAISES MORGAN ADVANCED TO SECTOR PERFORM ('UNDERPERFORM') - TARGET 275 (250) PENCE

----------

RBC CUTS ROTORK TO 'UNDERPERFORM' ('SECTOR PERFORM') - TARGET 275 (265) PENCE

----------

RBC RAISES IMI TO 'OUTPERFORM' ('SECTOR PERFORM') - TARGET 1140 (1000) PENCE

----------

GOLDMAN CUTS VIRGIN MONEY PRICE TARGET TO 95 (100) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES HOCHSCHILD MINING TARGET TO 180 (170) PENCE - 'NEUTRAL'

----------

JEFFERIES RAISES SPIRENT PRICE TARGET TO 325 (290) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

LIBERUM RESUMES MITIE GROUP WITH 'HOLD' - TARGET 43 PENCE

----------

BERENBERG RAISES CONNECT GROUP TO 'BUY' ('HOLD') - TARGET 27 (15) PENCE

----------

DEUTSCHE BANK CUTS FORTERRA PRICE TARGET TO 234 (340) PENCE - 'BUY'

----------

BERNSTEIN CUTS BOOHOO PRICE TARGET TO 350 (480) PENCE - 'OUTPERFORM'

----------

BERENBERG CUTS KENMARE RESOURCES PRICE TARGET TO 370 (380) PENCE - 'BUY'

----------

RBC CUTS CLINIGEN PRICE TARGET TO 1300 (1500) PENCE - 'OUTPERFORM'

----------

JPMORGAN CUTS HUNTING PRICE TARGET TO 210 (460) PENCE - 'NEUTRAL'

----------

RBC RAISES RESTAURANT GROUP TO 'OUTPERFORM' ('SECTOR PERFORM') - TARGET 80 (70) PENCE

----------

GOLDMAN CUTS BANK OF IRELAND PRICE TARGET TO 1.75 (2) EUR - 'NEUTRAL'

----------

GOLDMAN CUTS AIB GROUP PRICE TARGET TO 1.80 (2.20) EUR - 'BUY'

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
10 Oct 2019 10:50

Clinigen Inks Partnership To Sell Tumor Treatment Azedra Outside US

Clinigen Inks Partnership To Sell Tumor Treatment Azedra Outside US

Read more
3 Oct 2019 09:34

BROKER RATINGS SUMMARY: Peel Hunt Raises Flutter Entertainment To Hold

BROKER RATINGS SUMMARY: Peel Hunt Raises Flutter Entertainment To Hold

Read more
30 Sep 2019 09:55

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

Read more
19 Sep 2019 13:29

Thursday broker round-up

(Sharecast News) - Ferguson: RBC Capital Markets downgrades to underperform with a target price of 5,100p.

Read more
19 Sep 2019 10:36

Clinigen Profit Drops On One-Off Costs, Despite Strong Revenue Growth

(Alliance News) - Clinigen Group PLC said Thursday annual profit dropped sharply on higher amortisation costs on acquired intangibles and acquisition expenses, despite strong revenue the financial

Read more
12 Sep 2019 16:21

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 13 September  JD WetherspoonFull Year ResultsSthreeQ3 Enterprise Investment

Read more
16 Jul 2019 10:04

Clinigen Expects Increased Annual Profit On Strong Acquisitions

(Alliance News) - Clinigen Group PLC said Thursday it expects to see a double-digit rise in profit and revenue for its recently ended financial year, driven by contributions from the year to the a

Read more
16 May 2019 06:45

CORRECT: Clinigen Retakes Ethyol And Totect US Commercial Rights

(Correcting the headline to clarify that Clinigen already had the products in its portfolio).LONDON (Alliance News) - Clinigen Group PLC on Wednesday said it has agreed to retake the US to

Read more
15 May 2019 12:43

Clinigen to take back US rights to cancer drugs

(Sharecast News) - Aim's Clinigen Group is taking back control of two oncology drugs from US partner Cumberland Pharmaceuticals.

Read more
2 Apr 2019 10:57

Clinigen monopolises global rights for skin cancer treatment

(Sharecast News) - Clinigen now owns the global rights to Proleukin after having acquired the US rights to the treatment on Tuesday following US anti-trust clearance.

Read more
27 Feb 2019 10:23

Clinigen earnings grow following CSM and iQone acquisitions

(Sharecast News) - Specialty pharmaceuticals group Clinigen saw strong earnings and cash flow growth in the first half of its trading year following a period of transformative acquisitions.

Read more
27 Feb 2019 08:55

Clinigen Group Reports "Good" Interim Performance As Revenue Rises

LONDON (Alliance News) - Clinigen Group PLC on Wednesday described its interim performance as "good", with revenue rising 24%, but profit did fall on the prior year.For the six to

Read more
20 Feb 2019 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 21 February BAE SystemsFull Year ResultsRELXFull Year Year AmericanFull

Read more
20 Feb 2019 13:19

Wednesday broker round-up

(Sharecast News) - Ocado: Peel Hunt downgrades to hold with a target price of 110p.

Read more
13 Feb 2019 12:50

Wednesday broker round-up

(Sharecast News) - Workspace Group: Berenberg downgrades to hold with a target price of 900p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.